Your session is about to expire
← Back to Search
Nivolumab Maintenance for Diffuse Large B-Cell Lymphoma
Study Summary
This trial is for patients with DLBCL who have relapsed within 12 months of chemotherapy. The purpose of the trial is to use circulating tumor DNA (ctDNA) to detect relapse at an early stage, and to treat with Nivolumab to prevent complete relapse.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 541 Patients • NCT02041533Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have hepatitis B or C, or I was cured of hepatitis C.I had a stem cell transplant using my own cells more than 100 days ago.I haven't taken high-dose steroids or immunosuppressants in the last 14 days.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.I have had previous treatments like chemo, radiation, or a stem cell transplant.I have a specific type of lymphoma, with certain high-risk features, and a recent negative PET/CT scan.I've had treatments before, but my latest scans show no signs of cancer.I am older than 18 years.I can take care of myself but might not be able to do heavy physical work.I can provide a tissue sample of my tumor for analysis.I haven't had vaccines for infectious diseases in the last 4 weeks.I have no known allergies or adverse reactions to nivolumab.I have HIV but it is under control.I have been cancer-free from a second cancer, not including specific types, for over 3 years.I haven't had cancer treatment for at least 3 weeks.I agree to use birth control and avoid pregnancy or fathering a child during and for 18 weeks after treatment.I have an autoimmune disease or condition requiring steroids.I have had a transplant from another person.I have been treated with drugs targeting PD-1, PD-L1, or PD-L2.My blood counts and liver/kidney functions are within safe ranges.I finished my radiation therapy at least 2 weeks ago.
- Group 1: Nivolumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the threshold of people who can join this research endeavor?
"This study is no longer recruiting due to it's initial posting on May 15th 2018 and last update on August 8th 2022. However, there are 1782 trials targeting individuals with diffuse large b-cell lymphoma (dlbcl) and 717 studies related to Nivolumab IV 240 mg that remain actively seeking participants."
To what medical condition is Nivolumab, IV, 240 mg typically administered?
"Nivolumab, IV at a dosage of 240 mg is an effective treatment for malignant neoplasms such as unresectable melanoma and squamous cell carcinoma."
Has Nivolumab, IV, 240 mg been used in any previous clinical experiments?
"Currently, 717 live medical studies are assessing the efficacy of Nivolumab IV 240 mg with 83 trials in Phase 3. While some research sites for this drug are located in Basel, BE, 41196 locations around the world have opened trials to examine its effects."
Is this trial an inaugural effort towards a particular medical advancement?
"The pharmaceutical company Ono Pharmaceutical Co. Ltd kickstarted the research for Nivolumab, IV, 240 mg in 2012 with a clinical trial involving 659 patients. Following its successful completion and Phase 1 & 2 drug approval it has since been studied in 717 active trials across 2362 cities and 49 countries worldwide."
Is this research initiative currently recruiting participants?
"The information on clinicialtrials.gov confirms that this particular trial is not recruiting any participants at present, despite having posted and updated the study since its initial posting of May 15th 2018. Nevertheless, there are 2499 other medical studies actively enlisting volunteers right now."
Share this study with friends
Copy Link
Messenger